Communiqués Ionis Pharmaceuticals, Inc.

Actions

IONS

US4622221004

Recherche biotechnologique et médicale

Temps réel estimé Cboe BZX 19:45:03 21/08/2026			Varia. 5j.	Varia. 1 janv.
59,74 ^USD	+1,68%		+4,61%	-24,31%

20/08	Ionis Pharmaceuticals présente de nouvelles données sur la prise en charge de l'hypertriglycéridémie sévère au congrès 2026 de la Société européenne de cardiologie	CI
31/07	Ionis Pharmaceuticals : un administrateur acquiert des actions pour un montant de 1 058 700 $, selon un document de la SEC	MT

Communiqués

20/08	Ionis to present new data strengthening leadership in the management of severe hypertriglyceridemia (sHTG) at the European Society of Cardiology Congress 2026	BU
29/07	Ionis Pharmaceuticals: Q2 Earnings Snapshot	AQ
29/07	Ionis announces Dr. Frank Bennett, chief scientific officer, to retire	BU
29/07	Ionis reports second quarter 2026 financial results and highlights progress on key programs	BU
15/07	Ionis to hold second quarter 2026 financial results webcast	BU
14/07	Ionis Partner Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer’s Disease	BU
13/07	Ionis doses first participant in Phase 1-2 ASCEND study of ION337 in Dravet syndrome	BU
09/07	Update on CARDIO-TTRansform Phase 3 trial of eplontersen in adults with transthyretin-mediated amyloid cardiomyopathy	BU
06/07	Ionis completes enrollment in pivotal cohort of the Phase 3 REVEAL study evaluating obudanersen in Angelman syndrome	BU
25/06	TRYNGOLZA(R) (olezarsen) approved by the FDA as the first and only treatment to reduce triglycerides and the risk of acute pancreatitis in patients with severe hypertriglyceridemia (sHTG)	AQ
25/06	Ionis announces license agreement with Recordati for zilganersen in Alexander disease (AxD) in all countries outside the U.S.	BU
24/06	TRYNGOLZA® (olezarsen) approved by the FDA as the first and only treatment to reduce triglycerides and the risk of acute pancreatitis in patients with severe hypertriglyceridemia (sHTG)	BU
08/06	Ionis announces appointment of Ludwig Hantson, Ph.D. to Board of Directors	BU
05/06	Ionis to present new analyses from CORE and CORE2 pivotal studies supporting olezarsen for severe hypertriglyceridemia at upcoming congresses	AQ
04/06	Ionis to present new analyses from CORE and CORE2 pivotal studies supporting olezarsen for severe hypertriglyceridemia (sHTG) at upcoming congresses	BU
28/05	Ionis partner GSK announces bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatment for chronic hepatitis B	BU
14/05	Ionis partner Biogen announces topline results from Phase 2 CELIA study of diranersen (BIIB080): first study to show reduction in tau pathology and cognitive benefit in patients with early Alzheimer’s disease	BU
04/05	Ionis to host 2026 virtual Annual Meeting of Stockholders	BU
01/05	Ionis to present at upcoming investor conferences	BU
29/04	Ionis Pharmaceuticals : Q1 2026 Ionis Earnings Slides	PU
29/04	Ionis Pharmaceuticals: Q1 Earnings Snapshot	AQ
29/04	Ionis reports first quarter 2026 financial results and highlights progress on key programs	BU
28/04	Ionis partner GSK announces bepirovirsen accepted for Priority Review and granted Breakthrough Therapy Designation by U.S. FDA as a potential first-in-class medicine for chronic hepatitis B	BU
21/04	Ionis presents new data from pivotal study of zilganersen in Alexander disease (AxD) at AAN 2026 Annual Meeting	BU
15/04	Ionis to hold first quarter 2026 financial results webcast	BU